Crossref
Should We Call Every Cancer a Rare Cancer?
Journal of Clinical Oncology · 20.10.2026 · 44 (30) · 2891-2894
DOI: 10.1200/jco-26-00596 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.10.2026. Verfasst von Chadi Nabhan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Ryght AI, Inc, Anaheim, CA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Ryght AI, Inc, Anaheim, CA.
- Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina, Columbia, SC.
- Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.
ORCID-Profile: Chadi Nabhan, Vivek Subbiah
Zitieren
APA
Nabhan, C., & Subbiah, V. (2026). Should We Call Every Cancer a Rare Cancer?. Journal of Clinical Oncology, 44(30), 2891-2894. https://doi.org/10.1200/jco-26-00596
Vancouver
Nabhan C, Subbiah V. Should We Call Every Cancer a Rare Cancer?. Journal of Clinical Oncology. 2026;44(30):2891-2894. doi:10.1200/jco-26-00596
BibTeX
@article{Nabhan2026,
author = {Nabhan, Chadi and Subbiah, Vivek},
title = {Should We Call Every Cancer a Rare Cancer?},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {30},
pages = {2891--2894},
doi = {10.1200/jco-26-00596}
}
EUVIMED